Valor202020212022202320242025TTMGastos comerciales, generales y administrativos1.08 B1.02 B1.1 B1.16 B1.01 B962.4 M962.4 MInvestigación y desarrollo177.7 M122 M123.1 M122.5 M112.2 M95.4 M95.4 MBeneficio operativo115.4 M410.4 M78.9 M151.9 M112.9 M-1.12 B-1.12 BTotal de ingresos no operativos-17.2 M-53.5 M-92.5 M10.4 M900 K-27.5 M-13.2 MGastos por intereses, netos de intereses capitalizados-1.6 M-3 M02.9 M9.4 M9.5 M9.5 MIngresos no operativos, una vez deducidos los gastos por intereses1.6 M-23.8 M-39.4 M-2.9 M-9.4 M-23.8 M-9.5 MIngresos/gastos extraordinarios-17.2 M-26.7 M-53.1 M10.4 M900 K-13.2 M-13.2 MBeneficio antes de impuestos-296.7 M294 M-100.9 M-8.3 M-80.7 M-1.3 B-1.3 BParticipación en los beneficios———-1.9 M-1.5 M—-34.3 MImpuestos13.2 M389.6 M-8.2 M-3.9 M80 M104.4 M104.4 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-162.6 M-130.9 M-130.9 M-4.4 M-160.7 M-1.4 B-1.4 BOperaciones suspendidas—62 M-9.7 M-8.3 M-11.1 M-23.1 M-23.1 MBeneficio neto-162.6 M-68.9 M-140.6 M-12.7 M-171.8 M-1.43 B-1.43 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-162.6 M-68.9 M-140.6 M-12.7 M-171.8 M-1.43 B-1.43 BBeneficio básico por acción-1.19-0.52-1.04-0.09-1.25-10.29-10.29Beneficio por acción diluido-1.19-0.52-1.04-0.09-1.25-10.29-10.29Número medio de acciones ordinarias136.1 M133.6 M134.5 M135.3 M137.4 M138.5 M552.9 MAcciones diluidas136.1 M133.6 M134.5 M135.3 M137.4 M138.5 M553.3 MEBITDA369 M597.6 M261.5 M337.6 M438.8 M-784.7 M-784.7 MEBIT-15.8 M285.4 M-77.1 M-21.9 M112.9 M-1.12 B-1.12 BCosto de los ingresos3.25 B2.72 B3 B2.98 B2.83 B2.76 B2.76 BOtros costes de producción———————Amortización y depreciación (flujo de caja)384.8 M312.2 M338.6 M359.5 M325.9 M337.5 M337.5 M
Perrigo Company plc
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.